Araclon Biotech

AD/PD 2025

Araclon Biotech, a Grifols company, presented the results of its clinical validation study of ABtest-MS in populations with mild cognitive impairment, and of its ABvac40 vaccine regarding its impact on the progression of Alzheimer’s disease (AD) and Cerebral Amyloid Angiopathy (CAA) at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2025).

OUR MISSION

Araclon Biotech, a subsidiary of Grifols, is a company specialising in the research and development of methods for the early diagnosis and preventive treatment of Alzheimer’s disease.

AIDING THE EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE

We are pioneers in the development of assays based on the determination of amyloid peptides in plasma that help to detect early pathological changes of the disease, before the onset of symptoms.

RESEARCH INTO THE TREATMENT OF ALZHEIMER'S DISEASE

We are developing ABvac40, an active vaccine to prevent the disease or delay the onset of symptoms.